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ABSTRACT
The traditional design of nucleoside reverse transcriptase inhibitors (NRTI’s)
involves the synthesis of chain-terminated nucleoside analogs. HIV-RT has relatively low
fidelity which facilitates mutations that confer resistance towards NRTI’s, also, drug
promiscuity from NRTI’s result in various side-effects that lead to poor patient adherence
to treatment. We designed and tested two-component covalent inhibitors against HIV-RT.
Our inhibitor design results in higher specificity due to its binary approach, which has
previously been used in biosensing applications, where both components are necessary
for therapeutic effect, and lower chances for mutagenesis because of its inhibitory action.
The TCCI approach results in up to 93% inhibition of HIV-RT Furthermore, our inhibitor
design is highly modular and can be adjusted towards the therapeutic targeting of other
biopolymers.
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CHAPTER 1: INTRODUCTION
In 1959, a Bantu man died in Kinshasa, Belgian Congo of unknown causes. A
fellow female died of unknown causes in Kinshasa, Belgian Congo in 1960. Studies on
preserved tissues from these two individuals in 2008 found that both had succumbed to
HIV, making them the oldest proven cases of HIV infection. By modeling the genetic
differences between the two viral genome samples, it was determined that the HIV
epidemic started sometime in 1920’s Leopoldville (Kinshasa).1
In 1981, unusual cases of patients infected with pneumicystis carinii, and mucosal
candidiasis were rapidly growing. All of these patients where immunocompromised and
did not respond to treatment.2 It was not until 1982 that the CDC formally recognized
AIDS, and scientists at the Pasteur Institute recognized HIV as the causing agent in
1984.3 In 1986, clinical trials for AZT, developed in 1964 as a chemotherapeutic anticancer agent,4 as an antiretroviral agent and is approved as a drug by the FDA in 1987.
Initially, AZT appeared as the answer towards the containment and eventual defeat of the
AIDS pandemic, but it was soon found that HIV mutates inducing resistance to AZT.5 AZT
served as a mere life extension for HIV/AIDS infected patients until 1996 when highly
active antiretroviral (HAART) therapy was introduced. For thirty years AZT, a nucleoside
reverse transcriptase inhibitor, has been in the forefront in the fight against AIDS. While
AZT taken in combination with other antiretroviral drugs has prolonged the life of HIV
positive patients, however, HIV is still mutating and slowly making AZT obsolete. Other

1

NRTIs have been derived from AZT to combat AZT-resistant strands of HIV, yet these
drugs act through the same mechanism as AZT.
HIV Replication Cycle
HIV has a replication cycle composed of ten steps, fusion, uncoating, reverse
transcription, integration, transcription, RNA export, translation, assembly, release, and
maturation. Current therapies are able to attack the replication cycle at four of these steps,
fusion,6 reverse transcription,7,8 integration,9 and maturation.10 The most vulnerable steps
for therapeutics are reverse transcription and maturation.11
HIV Fusion and Uncoating
The viral envelope is spotted with glycoprotein spikes. Each spike has a trimeric
structure composed of three surface proteins collectively known as GP120 and three
transmembrane proteins known as GP41. GP120 is heavily glycosylated with N-linked
mannose residues that form a protective armor over its sensitive active sites.12
To enter the CD4+ t-helper cells, GP120 binds to the CD4 viral receptor and one
chemokine co-receptor on the host cell. Then, the hydrophobic domains on GP41 aid in
the fusion between the viral envelope and the host membrane. Upon fusion, the viral
capsid containing the viral genome and viral enzymes is released. Reverse transcription
is initiated within the viral capsid, where nucleotides from the host cell are imported by
dynamic pores on the capsid surface.13 The capsid undergoes an uncoating event
mechanically activated by the first strand transfer of reverse transcription14, and by
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cellular factors from activated CD4+ cells such as phosphorylation by MELK in the
intracellular environment lead to the release of the viral genome and enzymes.15
Reverse Transcription
The newly released viral RNA genome is transcribed into complementary DNA by
HIV reverse transcriptase (HIV-RT). HIV-RT has two active sites, a polymerase site where
complementary DNA is synthesized from either an RNA or DNA template and a RNase
H site that degrades RNA only when present as a RNA-DNA duplex. HIV-RT being a wellstudied enzyme is a prime target for therapeutics partly because it is present in the cytosol
of the host cell and partly because it is a low-fidelity enzyme. Over half of currently
approved anti-HIV drugs are reverse transcriptase inhibitors.16
Integration
After the viral genomic RNA is transcribed into dsDNA, the pre-integration complex
(PIC) is formed. The PIC consists of biomolecules of viral origin (viral DNA, Vpr, matrix,
and integrase) and a barrier to autointegration factor 1 from the host cell. The PIC is able
to enter the nucleus through the nuclear pore complex without interrupting the nuclear
membrane. Upon entering the nucleus, integrase inserts the viral genome in the host
genome, preferentially in areas of high transcription to form the provirus.17
Transcription, Export, and Translation
Transcription of the provirus is regulated by the long terminal promoter (LTR) which
possesses several binding sites for several cellular transcription factors necessary for T3

cell cellular activity. Transcription then results in the formation of full-length viral mRNA
which is responsible for the formation of several structural HIV proteins.
RNA, full, and incompletely spliced are exported out of the nucleus by viral protein
REV, while spliced RNA is transported via cellular mechanisms. REV is a viral protein
with cellular localization signal that aids in the transport of unspliced RNA from the
nucleus to the cytoplasm.18 Translation of viral RNA is initiated by the internal ribosome
entry site (IRES) during which host cell translation is suppressed allowing the efficient
synthesis of viral proteins.19
Assembly, Budding, and Maturation
The viral proteins are assembled via viral HIV-1 gag protein mediation. Gag
contains several binding sites for newly synthesized viral proteins and RNA to form the
spherical gag-polyprotein. Gag then interacts with cellular motor protein KIF4 and other
components of cellular trafficking pathways to exit the host cell through budding. During
the budding process, the virion acquires its transmembrane glycoproteins. After budding,
viral protease (HIV-PR) is activated, and the polyprotein is then cleaved which initiates
the maturation of the viral particle. During the maturation process, the viral capsid formed,
and viral RNA is reorganized into its dimeric form.20
HIV-1 Reverse Transcriptase Structure and Function
HIV-1 Reverse Transcriptase (HIV-RT) is a heterodimer composed of the p51 and
p66 subunits, each named by their corresponding molecular weights. HIV-RT has two
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enzymatic functions, a polymerase domain which copies DNA or RNA template and a
RNase H domain which cleaves RNA when present as a DNA-RNA duplex. Like other
DNA polymerases, HIV-RT requires the presence of both, a primer and a template21.
DNA synthesis is initiated by host tRNAlys3 acting as a primer after hybridizing with
the 18-nt primer binding site (PBS) on the viral RNA.22 The primer is then elongated to
the 5’-R region which upon terminating forms the negative strand stop. This first primitive
product is digested by RNase H, and the nascent DNA strand hybridizes to the 3’-R
region. This process known as the first jump occurs either by intermolecular or
intramolecular mechanisms. The primer then continues elongating along the viral RNA
template until it passes the polypurine rich (PPT) region where RNase H cleaves the PPT
region’s borders to create a unique positive RNA strand, and as elongation continues,
RNase H removes the complementary template. The PPT region along with other small
polypurine-rich RNA islands act as templates for the formation of the positive DNA strand
which elongates until the annealed tRNAlys3 is copied thus generating a positive DNA PBS
region. This is known as the plus-strand strong stop, and RNase H then removes the
tRNA. Positive DNA PBS then hybridizes with negative DNA PBS (second jump) forming
cDNA and positive DNA elongation continues. Then, strand displacement and or repair
and ligation results in the formation of a linear DNA duplex with long terminal repeats
(LTR’s). Often, HIV-RT makes double-stranded DNA from two different RNA genomes
resulting in viral recombination. This results in mutations that lead to multi-drug resistant
HIV.23
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Structurally, the p66 subunit contains both polymerase and RNase H active site.
The p51 subunit is a structural subunit. The polymerase domain contains four
subdomains, fingers, palm, thumb, and connection; the nucleic acid binding cleft includes
the previously mentioned four domains plus the RNase H domain. The nucleic acid
domain undergoes a conformation change when primer-template is present known as the
primer grip. This grip is formed by a highly conserved region, and mutations in this region
may affect polymerase and RNase H activity. The polymerase domain contains a triad of
aspartic acid residues (D110, D185, and D186) complexed with magnesium where D185
and D186 are highly conserved. R72 and K65 bind to the β and γ phosphates from
incoming dNTPs and are also highly conserved. Y115 discriminates between dNTPs and
rNTPs, while Q151 interacts with the incoming dNTP’s 3’-OH.
Nucleoside Reverse Transcriptase Inhibitors (NRTI’s)
NRTI’s are the first line of defense against HIV infection developed. Currently,
there are eight FDA approved NRTI’s: abacavir (ABC), didanosine (ddI), emtricitabine
(FTC), lamivudine (3TC), stavudine (d4T), zalcitabine (ddC), and zidovudine (AZT). The
first NRTI approved for HIV was AZT, also known as azidothymidine. AZT, first
synthesized in 196424 as a possible anti-cancer chemotherapeutic was approved by the
FDA in 1987 for the treatment of HIV/AIDS.
AZT, as well as other NRTIs, act upon HIV-RT as chain terminators due to the lack
of 3’-OH. When originally developed, AZT was used as a standalone antiretroviral; the
efficacy of AZT declined shortly thereafter because of viral mutations.25 With the
6

development of lamivudine, another NRTI, and protease, integrase, and non-nucleoside
reverse transcriptase inhibitors, the highly-active antiretroviral therapy (HAART) drug
regimen were introduced in 1996 to mitigate the proliferation of NRTI resistance and
extend the patient’s life. HAART consists of a combination of two NRTI’s and one
protease, integrase, or NNRT inhibitor. While HAART can suppress the virus for the
lifetime of a patient, mutations can still arise. Also, patients must adhere to HAART for
the rest of their lives.
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Figure 1. Commonly used nucleoside reverse transcriptase inhibitors (NRTIs)
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Resistance NRTI’s occurs via two mechanisms, pyrophosphorolysis mediated by ATP23
and increased discrimination between natural dNTPs and inhibitors. There are two types
of mutations which lead to resistance nucleotide associated mutations (NAMs) and
thymidine associated mutations (TAMs). TAMs are involved in the pyrophosphorolysis of
AZT and d4T and there are two distinct pathways leading to TAMs. Pathway 1 (M41L,
L210W, T215Y, and occasionally D67N) and pathway 2 (D67N, K70R, T215F, and
219E/Q).26–29 NAMs which discriminate between dNTPs and NRTIs arise from the
M184V/I and the K65R mutations. The M184V mutation discriminated between dNTPs
and 3TC or FTC.30 The K65R mutation discriminates against tenofovir, ddC, ddI, d4T,
and ABC31–34. These mutations decrease HIV-RT fitness, but the loss of activity can be
mitigated by the appearance of secondary mutations. The drive behind the development
of more NRTI’s lies in causing lethal mutagenesis, a viral particle that is no longer viable
due to the amount of mutations present.35
The Two-Component Covalent Inhibitor (TCCI) Approach
Most of the currently approved protein and nucleic acid inhibitors bind reversibly
to their targets to decrease biological activity. Ideally, the inhibitors will selectively bind to
their intended target only, but, they may also bind to non-specific targets and cause
serious side effects. The reversibility of these inhibitors also increases the probability of
mutations and development of drug-resistant pathogens. In this study, we propose to use
a novel approach towards the design of irreversible covalent drugs by taking advantage
of Two Component Covalent Inhibitors (TCCI’s) concept. TCCI’s show improved
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specificity and irreversibility of inhibition. The main idea behind this approach is the use
of two relatively unreactive chemical functional groups that would react with each other
when in close proximity and correct orientation when bound to a specific biopolymer. The
reaction between the pre-reactive groups forms a highly reactive electrophilic species
which is then open to the attack by nearby nucleophiles on the target protein or nucleic
acid. The specificity of the TCCI’s is determined by the chosen ligand analogs which can
be modified accordingly by adding the respective pre-reactive groups. We demonstrate
that the TCCI approach can be effectively used to covalently and selectively inhibit T4
DNA polymerase when using radiation activated TCCI, and HIV-RT when using
chemically activated TCCI systems.
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Figure 2. Light dependent TCCI dTTP analogs

The radiation activated TCCI was first developed by Evan Cornett at the
Kolpashchikov lab in 2012.36 This system consisted of two “pre-reactive” dTTP analogs
where the first analog contained a tetrafluoroazidobenzene (FAB) warhead, and the
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second contained a pyrene warhead. When T4 DNA polymerase was exposed to
radiation at 340 nm, the pyrene transferred energy to the FAB group generating a nitrene
radical37 which cross-linked and inactivated the enzyme. By calculating the specificity
factor for the TCCI approach and comparing the calculation for a single covalent inhibitor,
it was found that the specificity was increased by a factor of 11. This specificity was
demonstrated by an experiment where T4 DNA polymerase competed for a hairpin
substrate with T7 RNA polymerase. Inhibition of T4 DNA polymerase varied little up to
the presence of 4000:1 T7 RNA polymerase: T4 DNA polymerase, while single
component covalent inhibition showed marked promiscuity where inhibition of T4 DNA
polymerase dramatically decreased in the concentrations of T7 RNA polymerase became
high enough to limit the availability of the hairpin substrate.

Figure 3. TCCI scheme
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Figure 4. TCCI specificity assay
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CHAPTER 2: FIRST GENERATION TWO-COMPONENT COVALENT
INHIBITORS
Introduction
The radiation initiated TCCI has limited application due to the short penetration
range of violet light; leading to an effort to find a chemically activated TCCI. The first
generation of TCCIs was β-lactam derived dTTP analogs activated by nucleophiles. The
β-lactam approach yielded good results, but β-lactam’s ring instability led to
characterization problems. Both TCCI candidates were designed as HIV-RT inhibitors.
The β-lactam approach consisted of a dTTP analog containing clavulanic acid
first, but instability led to the design of a sulbactam derivative. Sulbactam required less
processing prior to amidation, and is reportedly more stable than clavulanic acid38–41.
The second dTTP analog containing a nucleophile (imidazole, thiol, or phenol). This
design was based on the mechanism of action of clavulanic acid and sulbactam were a
β-lactamase nucleophilic residue attacks the four-membered β-lactam ring and forms a
Michael acceptor that is readily attacked by a second nucleophilic residue as shown in
figure 5.42 We propose an analogous mechanism for the inactivation of HIV-RT, where a
nucleophilic dTTP analog recreates the nucleophilic attack by the serine residue on
either clavulanic acid or sulbactam dTTP analogs (figure 6). Several nucleophilic
residues where designed for this purpose, allylpropioimidazolamide dTTP (IM-dTTP),
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allyl-(2,3,5,6-tetrafluoro-4-hydroxy)benzamide dTTP (TF-dTTP), and 3mercaptopropionamide dTTP (3M-dTTP).
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Materials and Methods
Synthesis of 5-allylamine dTTP43: 5-allylamine dUTP was synthesized by using
adding dUTP (200mg, 0.36 mmol) and mercuric acetate (574 mg, 1.8 mmol) were
added to a 40 mL solution of 0.1 M sodium acetate at pH 6 and stirred for 4 hours at 50
o

C. The solution was then cooled over ice, and lithium chloride (142 mg, 3.25 mmol)

was added and stirred for 15 minutes to produce mercuric chloride. The mercuric
chloride was then removed by washing the aqueous layer six times with 40 mL of ethyl
14

acetate, and the mercurated dUTP was precipitated by cold ethanol overnight. The
mercurated dUTP pellets were then dried and resuspended in 50 mL of 0.1 M sodium
acetate at pH 5. 1.5 mL of pure allylamine (13.3 M) was slowly added to 8.5 mL of cold
4 M acetic acid. Neutralized allylamine (1.1 mL, 2.2 mmol) were then added to the
mercurated dUTP solution, followed by the addition of potassium tetrachloropalladate
(0.5 mmol) previously prepared by the addition of palladium (II) chloride (90 mg, 0.5
mmol) to a 4 mL solution containing potassium chloride (150 mg, 2 mmol). As the
solution progressed, palladium and palladium oxide precipitated turning the solution
metallic black. The reaction was allowed to stir at room temperature for 20 hours. Then,
the solution was filtered by a 0.45 mm-membrane syringe filter resulting in a yellow
filtrate. The filtrate was then diluted five times, and purified by anion exchange
chromatography while using DEAE Sephadex A-25 (General Electric) and a 0 – 0.6 M
gradient of triethylammonium bicarbonate (TEAB) buffer. The desired product eluted
between 0.25 M and 0.45 M TEAB. The eluant was then concentrated under vacuum at
40 oC and resuspended in N,N-dimethylformamide. The concentration of allylamine was
then determined by measuring absorbance at 290 nM while using ε290 = 8100.
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Transformation of clavulanic acid, potassium salt: For DCC couplings, free acids
or ammonium salts are required. Potassium clavulanate was then transformed into
ammonium clavulanate by cation exchange chromatography. 10.2 mg of potassium
clavulanate (Sigma) was dissolved in water and added to a column containing Amberlite
IR-120 cation exchange previously treated with 1M ammonium chloride (Fisher). Elution
of ammonium clavulanate was monitored by TLC. The resulting ammonium clavulanate
solution was then lyophilized to obtain a light-yellow powder.
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Figure 8. Transformation of potassium clavulanate into ammonium clavulanate
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Synthesis of 5-allylclavulanamide dTTP: 1 equivalent of ammonium clavulanate
was dissolved in 1 mL of N,N-dimethylformamide (Fisher) followed by the addition of 1.1
equivalents of N-hydroxysuccinimide (ACROS) and 1.2 equivalents of
dicyclohexylcarbodiimide and shaken until the formation of dicyclohexylurea (ACROS)
crystals were observed. The solution was then centrifuged at 12000 RPM at 4 oC, and
the supernatant was transferred to a fresh microcentrifuge tube containing 0.5
equivalents of 5-allylamine dTTP and 4 equivalents of DIPEA (Fisher) in N,Ndimethylformamide. This solution was shaken at room temperature until the
disappearance of the amine monitored by TLC/Ninhydrin stain. The resulting product
migrated to a Rf = 0.32 on aluminum backed, silica gel TLC plates when using a 3:1:1
water:n-propanol: ammonium hydroxide mobile phase. The product was precipitated by
dividing the solution into 200 mL aliquots in 2 mL microcentrifuge tubes and filling the
tubes with 2% lithium perchlorate in acetone. The tubes were then centrifuged at 12000
RPM at 4 oC, and the resulting pellets were washed three times with cold absolute
ethanol. The pellets were individually resuspended in 1 mL of water, and purified by
HPLC (JASCO) equipped with a C-18 reverse phase column (Phenomenex). The
product was eluted using a gradient 0.05M lithium perchlorate 0 – 30% acetonitrile in
water buffer, with the desired product eluting at 4% of the gradient. The fractions
containing the product of interest were combined and lyophilized overnight after flashfreezing in a round bottom flask. The product was then resuspended in a minimal
amount of water, transferred to a 2 mL microcentrifuge tube and precipitated with lithium
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perchlorate in acetone followed by two cold absolute ethanol washes and two cold
acetone washes to remove excess lithium perchlorate, and three washes with 1,1,2trichloro-1,2,2-trifluoroethane to remove remaining acetone and dried in a vacuum
desiccator for 30 minutes. Afterwards, the pellet was resuspended in 55 mL of
deuterium oxide (Sigma), and the sample was characterized by 1H-NMR, where
possible traces of the product of interest were observed along with degradation of the
product.
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Figure 9. Synthesis of 5-allylclavulanamide dTTP

Synthesis of 5-allylaminosulbactamide dTTP: Sulbactam (TCI America) 1
equivalent was dissolved in 1 mL of previously dried N,N-dimethylformamide containing
1.1 equivalents of N-hydroxysuccinimide and 1.2 equivalents of
dicyclohexylcarbodiimide and shaken for 30 – 60 minutes. The sample was then
centrifuged to separate the dicyclohexylurea side-product, and the supernatant was
transferred to a 2 mL microcentrifuge tube containing 0.5 equivalents of 5-allylamine
dTTP and 4 eq. of DIPEA. The mixture was allowed to react by shaking at room
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temperature for 2 to 4 hours, and the reaction was monitored by TLC and ninhydrin
stain, and the product was observed Rf = 0.33 when using the same system as above.
Upon the consumption of 5-allylamine dTTP, the reaction mixture was divided into 200
mL aliquots and precipitated by 2% lithium perchlorate in acetone. The tubes were
centrifuged at 12000 RPM at 4 oC for 5 minutes, and the supernatant was discarded.
Then, the pellets were washed three times with absolute ethanol and resuspended in
water for RP-HPLC purification using the same gradient system as with clavulanamide
dTTP. The product eluted on average at 19.5% (5.9% acetonitrile) of the gradient, tR=
9.9. After purification, the product was processed in the same fashion as the clavulanic
acid derivative. 5-allylsulbactamide dTTP was then characterized by 1H-NMR where a
mixture of decomposition products and traces of the product of interest were observed.
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Figure 10. Synthesis of allylsulbactamide dTTP

Synthesis of 5-allylpropioimidazolamide dTTP: 1 equivalent of Imidazole
propionic acid (TCI America) was dissolved in 1 mL of previously dried N,N-
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dimethylformamide containing 1.1 equivalents of N-hydroxysuccinimide and 1.2
equivalents of dicyclohexylcarbodiimide and shaken for 30 – 60 minutes. The sample
was then centrifuged to separate the dicyclohexylurea side-product, and the
supernatant was transferred to a 2 mL microcentrifuge tube containing 0.5 equivalents
of 5-allylamine dTTP and 4 eq. of DIPEA. The mixture was allowed to react by shaking
at room temperature for 2 to 4 hours, and the reaction was monitored by TLC and
ninhydrin stain, and the product was observed Rf = 0.29 when using the same system
as above. Upon the consumption of 5-allylamine dTTP, the reaction mixture was divided
into 200 mL aliquots and precipitated by 2% lithium perchlorate in acetone. The tubes
were centrifuged at 12000 RPM at 4 oC for 5 minutes, and the supernatant was
discarded. Then, the pellets were washed three times with absolute ethanol and
resuspended in water for RP-HPLC purification using the same gradient system as with
clavulanamide dTTP. The product eluted on average at 68% of the gradient (9.6%
acetonitrile) of the gradient, tR= 13 minuted. After purification, the product was
processed in the same fashion as above and was then characterized by 1H-NMR.
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Figure 11. Synthesis of allylpropioimidazolamide dTTP
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Synthesis of 5-allyl-(2,3,5,6-tetrafluoro-4-hydroxy)benzamide dTTP (TF): 1
equivalent of 2,3,5,6-tetrafluoro-4-hydroxybenzoic acid (Sigma) was dissolved in 1 mL
of previously dried N,N-dimethylformamide containing 1.1 equivalents of Nhydroxysuccinimide and 1.2 equivalents of dicyclohexylcarbodiimide and shaken for 45
minutes. The sample was then centrifuged to separate the dicyclohexylurea sideproduct, and the supernatant was transferred to a 2 mL microcentrifuge tube containing
0.5 equivalents of 5-allylamine dTTP and 4 eq. of DIPEA. The mixture was allowed to
react by shaking at room temperature for 16 hours, and the reaction was monitored by
TLC and ninhydrin stain, and the product was observed Rf = 0.47 when using the same
system as above. Upon the consumption of 5-allylamine dTTP, the reaction mixture was
divided into 200 µL aliquots and precipitated by 2% lithium perchlorate in acetone. The
tubes were centrifuged at 12000 RPM at 4 oC for 5 minutes, and the supernatant was
discarded. Then, the pellets were washed three times with absolute ethanol and
resuspended in water for RP-HPLC purification using the same gradient system as with
clavulanamide dTTP. The product eluted on average at 56% of the gradient (13.2%
acetonitrile) of the gradient, tR= 14 minutes. After purification, the product was
processed in the same fashion as previously reported dTTP analogs and characterized
by 1H-NMR, 19F-NMR, and 31P-NMR.

21

F
O
H2N

4 TEA

.

NH
N

P3O 10

O

O

O

+

O

OH

F

F

F

F

F

1. 1.1 eq. NHS HO
1.2 eq. DCC
F
2. 2 eq. DIPEA
DMF, RT

OH

F

4 Li

.

O

N
H

NH
N

P3O 10

O

OH

OH

Figure 12. Synthesis of allyl-(2,3,5,6-tetrafluoro-4-hydroxy)benzamide dTTP

Synthesis of 5-allyl-(3-mercapto)propionamide dTTP: 1 equivalent of 3mercaptopropionic acid (Sigma) was dissolved in 1 mL of previously dried N,Ndimethylformamide containing 1.1 equivalents of N-hydroxysuccinimide and 1.2
equivalents of dicyclohexylcarbodiimide and shaken for 60 minutes. The sample was
then centrifuged to separate the dicyclohexylurea side-product, and the supernatant
was transferred to a 2 mL microcentrifuge tube containing 0.5 equivalents of 5allylamine dTTP and 4 eq. of DIPEA. The mixture was allowed to react by shaking at
room temperature for 2 hours, and the reaction was monitored by TLC and ninhydrin
stain, and the product was observed Rf = 0.47 when using the same system as above.
Upon the consumption of 5-allylamine dTTP, the reaction mixture was divided into 200
mL aliquots and precipitated by 2% lithium perchlorate in acetone. The tubes were
centrifuged at 12000 RPM at 4 oC for 5 minutes, and the supernatant was discarded.
Then, the pellets were washed three times with absolute ethanol and resuspended in
water for RP-HPLC purification using the same gradient system as with clavulanamide
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dTTP. The product eluted on average at 56% (13.2% acetonitrile) of the gradient, tR= 16
minutes. After purification, the product was processed in the same fashion as the
clavulanic acid derivative. 5-allylsulbactamide dTTP was then characterized by 1H-NMR
and 31P-NMR.
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Figure 13.Synthesis of allylmercaptopropionamide

Substrate Properties and Inhibition
All substrate properties and inhibition assays were designed and implemented by
Evan Cornett at the Kolpashchikov lab.The following is a summary of those results.
Both, CL with IM and SU with TF showed significant attenuation of HIV-RT activity.
When CL and IM were used as TCCI pair, an average of 78% inhibition was observed,
while for the SU – TF pair, similar inhibition was observed.
Gel-Analysis of reactive pairs. 15 μL samples containing 50nM of HIV-1 RT
(Worthington Biochemical Corporation), 1 μM of FAM-primer(FAM-Primer: 5’/FAM/ GTC
CCT GTT CGG GCG CCA) and template (5’-C TGT GTG GTC GTT CTC TTG CTA
TGG GCG CCG AAC AGG GAC) in HIV RT RXN buffer (50 mM Tris pH8.3, 8 mM
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MgCl2, 40 mM KCl). FAM-primer was purified by HPLC. For CA - TF experiments, 5μM
of each CA, TF, or dTTP analog was added to the corresponding microtube, followed by
incubation at 37 °C. Aliquots of each sample were sequentially removed at different time
points (5, 10, 20 and 30 minutes) and 500μM of natural dNTPs were added. After
incubation at 37 °C for an additional hour, samples were quenched by addition of an
equal volume of 2X dPAGE Loading Buffer (LB) (95% Formamide, 20 mM EDTA (pH
8.0), 0.05% bromophenol blue). For SB-TF experiments the first analog was added to a
final concentration of 10 μM followed by 30 minute incubation at 37 °C. The second
analog was added to a final concentration of 100 μM followed by 60 minute incubation
at 37 °C. Next, 500 μM of all four natural dNTPs (dATP, dCTP, dGTP, dTTP) were
added to each sample, as indicated, and incubated for 60 minutes at 37 °C. To stop the
polymerase reaction, an equal volume of 2X dPAGE LB was added to each sample.
Control samples to evaluate elongation by one base were quenched with dPAGE LB
after the initial incubation period. For both CA and SB experiments, all samples were
boiled for 5 minutes prior to loading 15 μL onto a 15% 7 M urea denaturing PAGE gel
that was typically run for 45 minutes (or until sufficient separation as indicated by
migration of bromophenol blue) at 400 V with 55 °C water running through a Thermo
Owl Electrophoresis apparatus. Gels were rinsed in deionized water and visualized
using a Syngene U:Genius Gel documentation instrument which allowed detection of
the fluorescently labeled FAM-primer with no additional staining. The resulting gels were
analyzed by fluorescence of the corresponding analog or TCCI pair relative to the
fluorescence of the natural substrate elongation.
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Results and Discussion
The β-lactam derivatives were difficult to characterize due to their inherent
instability, especially in the presence of nucleophiles under the basic reaction condition
used for the N-acylation of allylamine dUTP. This led to poor proton NMR’s where not
all the expected signals were present. The analogs were still analyzed under dPAGE
and tested as possible candidates as TCCIs while awaiting improved synthetic
pathways.
The dPAGE analysis of the analogs shows that both β-lactam modified dTTP
analogs are efficient nucleotide analogs yielding approximately 82% product elongation
relative to dTTP incorporation after 30 minutes, while TF shows 84% elongation and IM
shows moderate inhibition at 45% elongation. When analogs were combined, a marked
inhibitory effect is noticed where the CL-TF pair shows only 25% elongation, IM-CL 16%
elongation, TF-SB 11% elongation.
The above results show that dTTP analog pairs (Nucleophile - β-lactam) inhibit
HIV-RT, but the β-lactam moiety is unstable. This inherent instability facilitates the
covalent inhibition of β-lactamases and possibly the inhibition of HIV-RT when used as
a TCCI, but hinders the synthesis of dTTP analogs via traditional DCC/NHS coupling
and subsequent product characterization.
Possible solutions for overcoming current synthetic difficulties are the
transformation of sulbactam or clavulanic acid into acyl chlorides followed by acylation
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of allylamine dideoxyuridine. The acyl chloride is more reactive than the strained βlactam and the lack of hydroxide groups on the nucleic acid analog eliminates
competing reactions. The drawback from this proposal is that substrate properties for
the analog cannot be tested because it would act as a chain terminator.
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CHAPTER 3: SECOND GENERATION TWO-COMPONENT COVALENT
INHIBITORS
Introduction
Azides and strained cyclooctynes are well known biorthogonal reagents used for
the labeling of proteins,44 glycosides,45 and nucleic acids.46 This led to the utilization of
6-Azidohexanamide dTTP (6Az-dTTP) and Dibenzocyclooctyne-amide dTTP (DBCOdTTP) as pre-reactive analogs against HIV-RT. The available literature does not
indicate any reactivity by azides, DBCO, or triazole click-product; except for a technical
brief from Glen Research that shows cleavage of DBCO from its internal amide linker in
the presence of iodine.
While testing this TCCI pair, inhibition rates between above 90% were observed
independent of the order of addition while individual analogs show little inhibition. Also,
this TCCI pair was well characterized and showed covalent cross-linking by Western
blot.
Methods and Materials
Synthesis of 6-azidohexanoic acid: 1.94g (10 mmol) of 6-bromohexanoic acid
(ACROS) and 1.3g (20 mmol) of sodium azide (ACROS) were added to 10 mL of
previously dried N,N-dimethylformamide (ACROS). The solution was stirred at room
temperature for 36h. The product was extracted with 15 mL of dichloromethane, and the
organic layer was washed three times with 20% aqueous lithium chloride and dried over
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anhydrous magnesium sulfate overnight at 4 oC. The solvent was then evaporated
under vacuum and the product characterized by 1H-NMR (ppm): 1.38 (m, 2H); 1.59 (m,
4H); 2.32 (m 2H); 3.23 (m, 2H); 10.47 (s, 1H) and 13C-NMR (ppm): 24.48; 26.47; 28.85;
34.18; 51.9; 180.00.
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Figure 14. Synthsis of 6-azidohexanoic acid

Synthesis of 5-allyl(6-azidohexanamide) dTTP (6-Az dTTP): 6-azidohexanoic
acid (mmol) was added to a 1 mL solution containing N-hydroxysuccinimide (mmol) and
dicyclohexylcarbodiimide (mmol) in N,N-dimethylformamide. The solution was rocked
for 30 minutes, and the solution was separated from dicyclohexylurea by centrifugation
at 10000 rpm for 5 minutes at 4 oC. The supernatant was then transferred to a tube
containing 200 µL 5-allylamine dUTP (46.8 mM solution in DMF), and trimethylamine
(mmol). The new reaction mixture was rocked for approximately 2h when consumption
of allylamine was observed by ninhydrin stain on TLC, Rf = 0.36. The resulting product
was purified by RP-HPLC, tr = 12 min (%), and characterized by 1H-NMR (ppm): 1.41
(m, 2H); 1.63 (m, 4H); 2.34 (m, 2H); 2.43 (m, 2H); 3.35 (m, 3H); 3.94 (m, 1H); 4.24 (m,
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3H); 4.70 (m, 2H); 6.34 (m, 2H); 6.44 (m, 1H); 7.93 (s, 1H). 31P-NMR (ppm): -19.94 (β); 10.71 (α); -4.83 (γ).
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Figure 15. Synthesis of allyl(6-azidohexanamide) dTTP

Synthesis of 5-allyl(6-(11,12-Didehydro-5,6-dihydrodibenzo[b,f]azocine-5-yl)-6oxohexanamide) dTTP (DBCO-dTTP): Dibenzocyclooctyne-acid (mmol) was added to a
1 mL solution containing N-hydroxysuccinimide (mmol) and dicyclohexylcarbodiimide
(mmol) in N,N-dimethylformamide. The solution was rocked for 30 minutes, and the
solution was separated from dicyclohexylurea by centrifugation at 10000 rpm for 5
minutes at 4 oC. The supernatant was then transferred to a tube containing 200 µL 5allylamine dUTP (46.8 mM solution in DMF), and diisopropylethylamine (mmol). The
new reaction mixture was rocked for approximately 2h when consumption of allylamine
was observed by ninhydrin stain on TLC, Rf = 0.36. The resulting product was purified
by RP-HPLC, tr = 33 min (30% acetonitrile), and characterized by 1H-NMR (ppm): 1.13
(m, 4H); 1.91 – 2.04 (m, 4H); 2.33 (m, 2H); 4.16 (m, 3H); 4.60 (m, 1H); 6.25 (m, 2H);
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7.12 (m, 1H); 7.35 (m, 4H); 7.56 (m, 1H); 7.76 (m, 1H). 31P-NMR (ppm): -19.97 (β); 10.74 (α); -5.01 (γ).
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Figure 16. Synthesis of DBCO-dTTP

Substrate Properties and Inhibition
Initial substrate properties and inhibitory action by the 6-Az dTTP and DBCO
dTTP TCCI was investigated by dPAGE of a fluorescein labeled primer/template, where
elongation of the primer was achieved by utilizing 6-Az dTTP and DBCO dTTP with little
loss of activity relative to dTTP, however, enzyme activity was lost upon loading of both
6-Az dTTP and DBCO dTTP analogs prior to the addition of dNTPs.
The substrate properties were tested by incubating each sample containing 5µM
dTTP or dTTP analog for 30 minutes at 37 oC in a solution containing fluorescein
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labeled primer/template (1mM), HIV-RT (50 nM), BSA 100 µg/mL, DTT (2 mM), and
HIV-RT buffer (50 mM Tris-HCl pH = 8, 100 mM KCl, and 8 mM MgCl2), followed by the
addition of 1.5 µL of 5 mM dNTPs (dATP, dCTP, and dGTP) to an aliquot (13.5 mL) of
the previously incubated mixture. The reaction mixtures were quenched by the addition
of loading buffer (70% formamide, 0.05% bromophenol blue, 29.95% glycerol, and 20
mM EDTA). The reaction mixtures were then boiled for 5 minutes in a water bath and
added to a 15% dPAGE. The gel was run at 400 V for 50 minutes
Similarly, inhibition assays were prepared by incubating either 6-Az dTTP or
DBCO dTTP added as the first analog and incubated for 30 minutes at 37 oC, followed
by the addition of the second analog and incubation for an additional 20 minutes. At the
conclusion of the second incubation, dNTPs were added followed by a 45-minute
incubation. The reaction mixtures were quenched by the addition of loading buffer, then,
the reaction mixtures were then boiled for 5 minutes in a water bath, and added to a
15% dPAGE. The gel was run at 400 V for 50 minutes.

Figure 17. Substrate and inhibition properties of 6-Az dTTP and DBCO-dTTP
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To determine the formation of protein-primer crosslink, Western blot was
employed. dTTP and two sets of analogs were added to solutions containing biotin
labeled hairpin substrate (1mM), HIV-RT (100 nM), BSA 100 µg/mL, DTT (2 mM), and
HIV-RT buffer. After 30 minutes of incubation at 37 oC, DBCO dTTP was added to one
of the solutions containing 6-Az dTTP, while 6-Az dTTP was added to one solution
containing DBCO dTTP. The mixtures were further incubated for 30 minutes.

Figure 18. Modified Western blot of HIV-RT upon the incorporation of 6-Az dTTP and
DBCO dTTP into a biotinylated DNA hairpin substrate

A filter binding assay (FBA)47 was employed to quantify primer elongation by
dNTPs after the addition of dTTP, analogs, and TCCI combinations. For the FBA, a
master mix containing fluorescein labeled primer/template (1mM), HIV-RT (50 nM), BSA
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100 µg/mL, DTT (2 mM), and HIV-RT buffer was aliquoted into six 15 mL portions:
Sample 1 (negative control), samples 2, 3, and 4 (dTTP, 6-Az dTTP, and DBCO dTTP
respectively), and samples 5 and 6 (6-Az-dTTP and DBCO dTTP). The samples were
incubated for 45 minutes at 37 oC. After the first step elongation, 15 mL of FBA master
mix (1 mM dTTP, 1 mM dATP, 1 mM dCTP, and 10 mM 3H-dGTP) was added to
samples 1 through 4 and incubated for an additional 45 minutes, while DBCO dTTP was
added to sample 5 and 6-Az dTTP was added to sample 6, and incubated for 30
minutes. After the 30 minutes elapsed, FBA master mix was added to samples 5 and 6,
and further incubated for 45 minutes, while samples 1 through 4 were quenched by the
addition of 30 mL of 0.5M EDTA and placed in ice. After finalizing the incubation of
samples 5 and 6, the samples were also quenched by the addition of 30 mL of 0.5 M
EDTA. All samples were then added to anion exchange filter papers (Whatman, DE81)
and allowed to air dry. The dried filter papers were then washed twice with two 50 mL
portions of 0.5 M sodium phosphate buffer at pH 6.8, followed by one ethanol wash.
After washing, the filter papers were oven dried. Once dry, the filter papers were all
placed in 25 mL scintillation vials, and 7 mL of BD scintillation cocktail was added.
Radiation was then measured by a scintillation counter (Beckmann 5900), and the
reported values in counts per minute (CPM) were normalized to the value given by
sample 2 which contains natural substrates. The experiment was run in triplicate to
ensure statistical significance, and normalized to the elongation of natural dNTPs.
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Incorporation of [8-3H]-dGTP
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Figure 19. Filter binding assay measuring the incorporation of tritiated dGTP

A study comparing the click-TCCI with AZT was conducted where HIV-RT was
incubated with dTTP for 45 minutes followed by the addition of 5mM dNTPs containing
10 µM of tritiated dGTP and further incubated for three hours to serve as a positive
control. Two TCCI samples prepared by the addition of 6-Az dTTP as the first analog
and DBCO dTTP as the second analog after a 45 minute incubation were incubated for
30 minutes to ensure maximum cross-linking; one 1.5 µL aliquot of dNTPs were then
added to the first sample, while a 3 µL aliquot was added to the second and the
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template concentration was doubled. Similarly, two samples were incubated containing
AZT for 45 minutes followed by the addition of dNTPs for the first AZT sample or
doubled addition of dNTPs and template for the second sample. Like the inhibition
assay above, the samples were quenched, transferred to anion exchange filter papers
and radiation counts were measured.
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Figure 20. FBA comparing the efficacy of AZT against the click-TCCI system

The specificity of the inhibitor was studied by a filter binding assay. Samples
containing 50 nM HIV-RT or 50nM HIV-RT plus either 1000 nM, 5000 nM, or 10000 nM
T7 RNA polymerase were incubated in the presence of dTTP (50 nM HIV-RT only),
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DBCO dTTP, and TCCI when 6-Az dTTP was added first. The samples were first
incubated for 30 minutes with dTTP, DBCO dTTP, or 6-Az dTTP. Then, DBCO dTTP
was added to the sample containing 6-Az dTTP, and all samples were further incubated
for 30 minutes. FBA master mix was then added to all samples and incubated for 30
minutes. The reaction was quenched by adding an equivalent volume of 0.5M EDTA.
The samples were then transferred to a Whatman DE81 anion exchange filter disc and
dried in the oven for 20 minutes at 50 oC. The dried filters were then washed five times
in 50 mL of pH 6.8 sodium phosphate buffer followed by two ethanol washes and oven
dried for 20 minutes. The filter discs were then placed in 25 mL glass scintillation vials,
and 7 mL of scintillation cocktail was added. The samples were then analyzed by using
a Beckmann 5000 liquid scintillation counter.
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Figure 21. Specificity assay for the click-TCCI system, where the click-TCCI inhibition is
unaffected by the presence of T7 RNA polymerase
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Results and Discussion
Substrate properties of the individual analogs show equivalence to dTTP as they
are efficiently incorporated into the template, and the template is fully elongated
following analog incorporation even in the absence of dTTP. However, when both
analogs are used in conjunction, enzyme activity is lost and no other dNTPs are able to
incorporate even when dTTP is present in excess concentrations independent of the
order of addition. We believe that this is due to a combination of cross-linking of the
DBCO-dTTP analog and the formation of a bulky click-product in the presence of the
6Az-dTTP analog. The selectivity of the TCCI is demonstrated in the presence of T7
RNA polymerase where inhibition was unaffected by the presence of up to 200 times
excess T7 RNA polymerase. Another important advantage of the TCCI is the
demonstrated superiority over AZT. When the TCCI was incubated after the increased
concentration of primer-template and dNTPs, the activity of HIV-RT did not increase
whereas the activity of HIV-RT increased almost threefold in the presence of AZT. HIVRT shows ~7% activity in the presence of the TCCI independent of the order of addition
which is comparable to the ~5% activity when HIV-RT is incubated with AZT.
The DBCO dTTP/6-Az dTTP TCCI demonstrate the potential application of
TCCIs as anti-retroviral therapeutics. The inference from the dPAGE experiments
shows that the mechanism of action likely proceeds via nucleophilic acyl substitution of
the amide on the DBCO linker adjacent to cyclooctyne.
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CHAPTER 4: CONCLUSION
Reagent-based TCCIs are attractive alternatives to the traditional design of
drugs. While the current study is limited to nucleotide analogs, the system is highly
modular and can be applied towards the design of therapeutics against other
biologically relevant targets.
Some of the challenges of TCCI development lie in the reactivity of the analogs
with the amine linker, as in the case of the β-lactams. This problem may be avoided by
transforming the carboxylic acid into an acyl chloride. This approach would require
protection of any hydroxides on the thymidine derivative.
The click-reaction-based TCCI clears some the hurdles above by using
seemingly unreactive analog warheads which unexpectedly inhibited the intended
target. While these analogs function as TCCI’s, it is not known if inhibition is caused by
the covalent cross-link, or if the covalent cross-link merely aids with the inhibition by
providing an anchoring site for a bulky click triazole product to form which inherently
covalently blocks the DNA polymerase active site. Yet, the click-reactive analogs act
specifically against HIV-RT since there is little deviation in inhibition when in the
presence of up to 200 time excess T7 RNA Polymerase, and the complete elongation of
the substrate is unchanged when DBCO dTTP is added without 6-Az dTTP.
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CHAPTER 5: PROPOSED RESEARCH
Introduction
Chain-terminating nucleotide analogs must meet five requirements to be
considered as good therapeutic candidates, they must possess high catalytic efficiency,
no potential for elongation following incorporation, poor excision upon incorporation,
high selectivity towards target DNA polymerase, and effective metabolism of parent
nucleoside. While there are two main pitfalls concerning chain-terminators, resistance
development, and promiscuity leading to side effects.
The inherent side-effects of chain terminators, in general, arise from
incorporation by mitochondrial DNA polymerase-γ, which shares many conserved
regions with more primitive viral polymerases. A comparative study shows that
Lamiduvine, a chain-terminating NRTI used against HIV-RT, has an effective
incorporation rate of 0.019 against HIV-RT, while polymerase-γ shows an effective rate
of 0.009. This means that Lamivudine is only 2.1 times more selective towards HIVRT.48 Other side-effects are caused by poor metabolism, for example, the AZT-MP is a
competitive inhibitor of thymidine kinase which leads to depletion of dTTP. This
inhibitory effect is caused by the bulkiness of the 3’-azide group.49,50
We propose to synthesize chain-terminating 2’,3’-dideoxythymidine twocomponent covalent inhibitors based on the click-TCCI system. The TCCI system
shows that selectivity is greatly enhanced when a binary reagent is used, therefore
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reducing the possibility of promiscuity. The analogs presented in this publication also
show that they are high catalytic efficiency based on their substrate properties, low
concern for excision due to covalent inhibition.scale synthesis of analogs and HIV-RTTCCI adduct can be utilized to confirm the mechanism of action of the TCCI (citation).
Materials and Methods
5-base-modified-2’,3’-dideoxythymidine analogs are synthesized from their
parent nucleoside 2’,3’-dideoxy-5-iodouridine which acts as a good substrate for either
palladium coupling with allylamine or propargyl amine.51,52
Preparation of 5-iodo-2’,3’-dideoxyuridine(I-ddU): To a stirred solution of 2’,3’dideoxyuridine (500 mg, 2.36 mmol) in 10 mL of DMF, add N-iodosuccinimide (740 mg,
3.21 mmol), and lithium azide from 20% aqueous solution by wt. (1.44 mL, 6.42 mmol)
and stirred for 16 hours. The reaction is then quenched by the addition of aqueous
sodium nitrite, concentrated under vacuum, and purified by silica gel chromatography by
using a methanol: dichloromethane solvent system.
O

O
NH

N
HO

O

O

I

1.4 eq. LiN3
2.7 eq. NIS

NH
N

HO

DMF/H2O
RT, 16h

Figure 22. Synthesis of 5-iodo ddU
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Preparation of 5-allylamine-2’,3’-dideoxyuridine(aa-ddU): To a solution of I-ddU
(338 mg, 1.0 mmol) with cuprous iodide (38 mg, 0.2 mmol) in 5 mL of DMF, add
allylamine (225 µL, 3.0 mmol), triethylamine (279 µL, 2.0 mmol), and
tetrakis(triphenylphosphine)palladium (0) (116mg, 0.1 mmol) and stir at room
temperature for 4 hours. After reaction completion, the product is concentrated under
vacuum and purified by silica gel chromatography.
O

O
NH
N
HO

O

O

0.2 eq. CuI
3 eq. Allylamine
2 eq. TEA

NH

H2N
N
HO

Pd(PPh3)4
DMF, RT

O

O

Figure 23. Synthesis of 5-allylamine ddU

Synthesis of Synthesis of 5-allyl(6-(11,12-Didehydro-5,6dihydrodibenzo[b,f]azocine-5-yl)-6-oxohexanamide-2’,3’-dideoxythymidine: DBCO-acid
(40 µmol), N-hydroxysuccinimide (44 µmol), and dicyclohexylcarbodiimide (48 µmol) are
added to a microcentrifuge tube containing 800 µL of dry DMF and placed on a shaker
for 10 minutes. The supernatant is then transferred to another tube containing aa-ddU
(10 µmol) and DIPEA (20 µmol) in 200 µL of dry DMF. The reaction is then allowed to
shake at room temperature for 1 – 5h while monitored by the disappearance of amine
by TLC/ninhydrin stain. The product is then purified by HPLC equipped with a SHARC-1
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hydrogen bonding column utilizing a 100% to 75% acetonitrile – methanol gradient
containing 0.5% formic acid and 0.05% ammonium formate. The purified product is then
characterized by H-NMR and overnight C-NMR.
HO

O

O

N
HO

1. 1.1 eq. NHS
1.2 eq. DCC
2. 2 eq. DIPEA

NH

H2N
O

O

+

O

N

DMF, RT

O

O
N
O

N
H

NH
N

HO

O

O

Figure 24. Synthesis of DBCO-ddT

Synthesis of 5-allyl(6-azidohexanamide)-2’,3’-dideoxythymidine: 6-azidohexanoic
acid (40 µmol), N-hydroxysuccinimide (44 µmol), and dicyclohexylcarbodiimide (48
µmol) are added to a microcentrifuge tube containing 800 µL of dry DMF and placed on
a shaker for 10 minutes. The supernatant is then transferred to another tube containing
aa-ddU (10 µmol) and DIPEA (20 µmol) in 200 µL of dry DMF. The reaction is then
allowed to shake at room temperature for 1 – 5h while monitored by the disappearance
of amine by TLC/ninhydrin stain. The product is then purified by HPLC equipped with a
SHARC-1 hydrogen bonding column utilizing a 100% to 75% acetonitrile – methanol
gradient containing 0.5% formic acid and 0.05% ammonium formate. The purified
product is then characterized by H-NMR and overnight C-NMR.
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1. 1.1 eq. NHS N3
1.2 eq. DCC
2. 2 eq. DIPEA

+

DMF, RT

O

O
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N
H
N
HO
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Figure 25. Synthesis of allyl(6-azidohexanamide) ddT

Preparation of 5- N-Allyl-N,N-bis(trimethylsilyl)amine-2’,3’-dideoxyuridine(aaSiddU): To a solution of I-ddU (338 mg, 1.0 mmol) with cuprous iodide (38 mg, 0.2 mmol)
in 5 mL of DMF, add N-Allyl-N,N-bis(trimethylsilyl)amine (741 µL, 3.0 mmol),
triethylamine (279 µL, 2.0 mmol), and tetrakis(triphenylphosphine)palladium (0) (116mg,
0.1 mmol) and stir at room temperature for 4 hours. After reaction completion, the
product is concentrated under vacuum and purified by silica gel chromatography.
O

O
NH
N
HO

O

0.2 eq. CuI
3 eq.
2 eq. TEA

O

(H3C)3Si
NH
N
Si(CH3)3
N
Si(CH3)3
N
O
Si(CH3)3
HO
O

Figure 26. Synthesis of 5- N-Allyl-N,N-bis(trimethylsilyl)amine-2’,3’-dideoxyuridine
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Preparation of 5’-O-protected aaSI-ddU: aaSi-ddU (100 mg, 0.244 mmol) is
dissolved in 1 mL dry DMF with DIPEA (85 µL, 0.488 mmol). 2-(2-Nitrophenyl)propyl
chloroformate (119 mg, 0.488 mmol), a photolytic protecting group, is added to the
reaction vessel and allow to react for 30 minutes at room temperature in the dark. The
product is then purified by column chromatography in a dark environment and the
solvent is evaporated under vacuum. The product is then characterized by H-NMR and
C-13 NMR.
O
(H3C)3Si

N
Si(CH3)3
N
HO
O

O

O

(H3C)3Si

NH
O

+

O
NO 2

Cl

2eq. DIPEA
DMF, RT

NO 2
O

N
Si(CH3)3
N
O
O
O

Figure 27. Synthesis of 5’-O-protected aaSI-ddU

Removal of trimethylsylil-N-protecting groups: O-protected aaSi-ddU is placed in
a 1M TBAF/THF solution for 72h under vacuum in the dark, and purified by silica gel
column chromatography to yield deprotected allylamine. The product is then
characterized by H-NMR.
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Si(CH3)3
N
O
O

NH

H2N
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O
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O
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N
O

O

O

O

Figure 28. N-deprotection of 5’-O-protected aaSI-ddU

Synthesis of sulbactam acyl chloride: Sulbactam (117 mg, 0.5 mmol) is dissolved
in 1 mL of dichloromethane and cooled to -20 oC. 2 µL of DMF is added to the reaction
vessel, followed by the slow addition of oxalyl chloride (42.3 µL, 0.5 mmol) over 15
minutes. The reaction is then allowed to stir for 5h to afford the acyl chloride derivative.
O
O
N
S
O O

OH

O
(COCl)2
DMF

Cl

O
N

CH2Cl2, -20 oC
5h

S
O O

Figure 29. Synthesis of sulbactam, acyl chloride

Synthesis of 5-allylsulbactamide-2’,3’-dideoxythymidine: Sulbactam acyl chloride
(20 µmol) is dissolved in 1 mL dry DMF containing O-protected aa-ddU (10 µmol) and
DIPEA (11 µmol) as a chloride scavenger. The reaction is allowed to shake in the dark
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at -20 oC until the disappearance of amine by TLC/ninhydrin stain. Upon reaction
completion, the reaction is quenched by the slow addition of 1 mL of aqueous 5%
sodium bicarbonate. The derivative is then deprotected by irradiation at 365 nm for 30
minutes at 0 oC. The product is then purified by HPLC equipped with a SHARC-1
hydrogen bonding column utilizing a 100% to 75% acetonitrile – methanol gradient
containing 0.5% formic acid and 0.05% ammonium formate at 4 oC. The purified product
is then characterized by H-NMR and overnight C-NMR.
O O
S
O
NH

H2N
NO 2
O

O

N
O

O

O

O
N

+

S
O O

Cl

1. DIPEA
O
2. NaCHO3
λ = 365 nm

O

N
O

N
H

DMF
-20 oC - 0 oC

NH
N

HO

O

O

Figure 30. N-acylation of 5’-O-protected aaSI-ddU with sulbactam followed by Odeprotection

Synthesis of 5-allylimidazole propionamide-2’,3’-dideoxythymidine: Imidazole-4acetic acid (40 µmol) is added to a microcentrifuge tube containing NHS (44 µmol) and
DCC (48 µmol) in 800 µL of dry DMF. The reaction is placed on a shaker for 10
minutes, and the supernatant is transferred to a tube containing aa-ddU (10 µmol) in
200 µL of dry DMF and DIPEA (40 µmol). The reaction is allowed to shake while
monitored by TLC/ninhydrin stain. The product is then purified by HPLC equipped with a
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SHARC-1 hydrogen bonding column utilizing a 100% to 75% acetonitrile – methanol
gradient containing 0.5% formic acid and 0.05% ammonium formate. The purified
product is then characterized by H-NMR and overnight C-NMR.
O

N
HO

O

NH

H2N
O

O

HO

+

NH
N

1. 1.1 eq. NHS
1.2 eq. DCC HN
2. 2 eq. DIPEA

O

N

DMF, RT

O

N
HO

Figure 31. Synthesis of allyl(3-imidazolamide) ddT

Determination of Mechanism of Action
We propose to study the mechanism of action of TCCIs on HIV-RT via two
approaches: molecular docking and MALDI-TOF analysis of HIV-RT digestion
fragments. Protein mass fingerprinting (PMF) is a mass spectrometry technique
commonly used to determine the amino acid sequence of proteins #.53–55 Proteins are
chemically digested by proteases to give hydrolyzed fragments that can be analyzed
with the software aid. In recent years, there has been an increase of utilizing the same
protein sequencing techniques to determine covalently modified residues in proteins.56
When comparing the data obtained from HIV-RT covalently modified with TCCIs, the
resulting pattern is compared to known fragmentation patterns from databases. The
modified residues result in higher molecular weights relative to the fragments from the
database. These higher molecular weight fragments are then studied to determine the
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NH

N
H
O
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presence of possible nucleophilic amino acid residues. The determination of the
mechanism is further complimented by molecular modeling of the reaction within the
catalytic core of HIV-RT. Existing models from X-ray crystalline structure data are used
as a base for the docking of each of the TCCI components. The data obtained from this
experiment is used to determine why is inhibition achieved only when both TCCI
reagents are used, and why does the cyclooctyne dTTP analog form a reversible
covalent bond. The study can also serve as a platform for the in-silico development and
validation of other TCCIs.
Inhibitory Assays with Cell Lines
HIV-RT can serve as a substitute for DNA polymerase I in E.coli.57–59 This
enables the study of HIV-RT inhibitors in-vivo without the need for high biosafety level
clearance while minimizing the exposure to HIV infected CD4 cells. By inhibiting HIV-RT
in transformed cells, an increase in apoptosis would be observed, and the effectiveness
of the TCCI can then be determined and compared to the effectiveness AZT without
further modification. This assay also allows for the testing of the TCCI against mutant
HIV-RT strains that show resistance towards the current line of nucleoside reverse
transcriptase inhibitors. Also, limited toxicity studies on the TCCI can be studied by
testing the nucleoside analogs on wild-type E.coli.
Transformation of cells: The JS 200 strain of E. coli. Carries a temperature
sensitive allele of DNA polymerase I (Pol Its) where the cells can grow at 30 oC, but not
37 oC or above. By complementing the cells with viral, eukaryotic, or prokaryotic DNA
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polymerases, the transformed E. coli. cells can survive at higher temperatures. An
aliquot of JS 200 cells are electroporated in the presence of the pHIV_pTp66p51
plasmid kit from addgene. The cells are then resuspended in LB media and placed in a
shaker for 1h at 30 oC. Plate 1:0 and 1:1000 dilutions of cells on LB tetracycline
chloramphenicol plates and incubate for 1h. Remove two single colonies from each
plate and add to 5 mL of LB broth containing tetracycline and chloramphenicol and
incubate overnight at 30 oC followed by shaking at 30 oC for 1 to 2 hours. To test for
temperature sensitivity, inoculate a spiral of cell dilutions on two LB tetracycline
chloramphenicol X-Gal agar plates where one plate is preheated at 30 oC and the
second at 37 oC. Then both plates are incubated at their respective temperatures.
Successful plasmid incorporation is indicated by growth at 37 oC and blue coloration of
the cells.

A

B

C

D

E

Figure 32. Transformation of competent JS200 e.coli cells. A) A microcentrifuge tube
containing competent JS200 cells and pHIV_pTp66p51 plasmid kit are electroporated

to obtain B. Solution B is then inoculated on an LB plate C with X-gal, and
incubated for 1h at 30 oC to obtain D. Viable colonies with distinct blue coloration
are then collected in microcentrifuge tubes and frozen for later use E.
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Inhibition Assays: Batches of LB media with tetracycline, chloramphenicol, and
X-Gal are prepared to contain no inhibitor, AZT, or TCCI nucleosides. Aliquots of
transformed cells are inoculated in a spiral and incubated for 1 – 24h at 37 oC. Normal
cell growth occurs in plates containing no inhibitor, but the presence of inhibitors results
in apoptosis.

A

B

C

Figure 33. In-vivo testing of TCCI. Three LB plates are innoculated and incubated at 37 oC
with previously transformed JS200 cells A to give bacterial plates B. The plates are then
incubated in the presence of no inhibitor (top), AZT (middle), and TCCI (bottom) to give
plates C, where a decrease in number of colonies should be observed.
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APPENDIX A: NMR DATA
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Figure 34. Proton NMR for potassium clavulanate
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Figure 35. Proton NMR of 5-allylclavulanamide dTTP
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Figure 36. Proton NMR of sulbactam
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Figure 37. Proton NMR of 5-allylsulbactamide dTTP
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Figure 38. Proton NMR of 5-allyl-(2,3,5,6-tetrafluoro-4-hydroxy)benzamide dTTP
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Figure 39. Fluorine-19 NMR of 5-allyl-(2,3,5,6-tetrafluoro-4-hydroxy)benzamide dTTP

57

Figure 40. Proton NMR of 6-azidohexanoic acid
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Figure 41. Proton NMR of 5-allyl(6-azidohexanamide) dTTP
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Figure 42. Phosphorus 31 NMR of 5-allyl(6-azidohexanamide) dTTP
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Figure 43. Proton NMR of 5-allyl(6-(11,12-Didehydro-5,6-dihydrodibenzo[b,f]azocine-5-yl)6-oxohexanamide) dTTP
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Figure 44. Phosphorus 31 NMR of 5-allyl(6-(11,12-Didehydro-5,6dihydrodibenzo[b,f]azocine-5-yl)-6-oxohexanamide) dTTP
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